Jonathan Beer
Senior Director, Precision Medicine Bristol Myers Squibb
Jonathan Beer has over 25yrs experience in diagnostic/Companion Diagnostic development across the pharmaceutical and diagnostics industries. Joining Bristol Myers Squibb in 2023, he leads the diagnostic strategy and CDx development for multiple global investigational new drug clinical trials across technology and sample types. Prior to BMS, he was with Novartis for more than a decade and was the lead for the CDx assay for alpelisib which was the 2nd liquid biopsy CDx approved by the US FDA. Jonathan is a member of the BLOODPAC consortium and shares their mission to help improve patient outcomes through the use of Liquid Biopsies.
Seminars
Tuesday 31st March 2026
Panel Discussion: Aligning with Physicians, Payers, & Regulators to Strengthen an Integrated Roadmap for Drug– Diagnostic Value & Access
4:50 pm
- What is the biggest barrier each stakeholder sees when drugs and diagnostics are developed or evaluated in silos, and how do we overcome these disconnects?
- When Rx-Dx don’t launch together, what are the downstream consequences for physicians, patients, and payers, and how can these be prevented?
- What lessons from HER2, EGFR, and PD-L1 can we apply today, and what pitfalls must be avoided as we move toward more complex biomarkers like multimodal and AI-driven diagnostics?
Tuesday 31st March 2026
Liquid Biopsy Enabling Precision Oncology Clinical Trials
11:40 am
- Defining ctDNA guided clinical trial designs and assay performance requirements for each
- Showcasing ctDNA as a key secondary endpoint of th e TRIDENT-1 clinical trial, a case study discussion
- Partnering on the development of a WGS MRD distributed kit
